Drug Trial Radar · NCT07182682
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Sep 2029
Study completion Jan 2031
Sponsor
- Lead sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) or P-loop and αC-helix compression (PACC) mutations, who have had radical surgery, regardless of adjuvant chemotherapy.
Conditions
- Non-Small Cell Lung Cancer
Interventions
sunvozertinibDrug
Participants will receive oral administration of sunvozertinib 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
Matching PlaceboDrug
Participants will receive oral administration of placebo 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS) by investigator assessmentTime frame: Up to approximately 5 years after the first participant is randomized
Locations
49 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Not yet recruiting
Beijing Chest Hospital, Capital medical university
Beijing, China · Not yet recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Not yet recruiting
China-Japan Friendship hospital
Beijing, China · Not yet recruiting
Peking Union Medical College Hospital
Beijing, China · Not yet recruiting
Xuanwu Hospital Capital Medical University
Beijing, China · Not yet recruiting
The First Hospital of Jilin University
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Not yet recruiting
The Third Xiangya Hospital of Central South University
Changsha, China · Not yet recruiting
Xiangya Hospital of Central South University
Changsha, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, China · Not yet recruiting
West China Hospital Sichuan University
Chengdu, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, China · Not yet recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Not yet recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China · Not yet recruiting
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Not yet recruiting
Anhui Provincial Cancer Hospital
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
Yunnan Cancer Hospital
Kunming, China · Not yet recruiting
Jiangxi Provincial People 's Hospital
Nanchang, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, China · Not yet recruiting
Nanjing Chest Hospital
Nanjing, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, China · Not yet recruiting
Shanghai East Hospital
Shanghai, China · Not yet recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, China · Not yet recruiting
Liaoning Cancer Hospital & Institute
Shenyang, China · Not yet recruiting
The First Hospital of China Medical University
Shenyang, China · Not yet recruiting
Shanxi Cancer hospital (Shanxi Cancer institute)
Taiyuan, China · Not yet recruiting
Shanxi Provincial people's hospital
Taiyuan, China · Not yet recruiting
Taizhou Hospital, Zhejiang Province
Taizhou, China · Not yet recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.